GEN Exclusives

More »

The Lists

More »
Sep 23, 2013

Top 40 Molecular Millionaires

Who’s stocking up on biopharma stock?

Top 40 Molecular Millionaires

We’ve doubled our list from last year and this time included all categories of shares of common stock. [AlienForce - Fotolia.com]

  • Following is a list of 40 executives of publicly traded biopharma drug developers and tools/technology companies, ranked by the total value of their shares of common stock as stated on the companies’ proxy statements or Form 20-F statements. Each executive is listed with their title and company, the total value of their shares of common stock, the number of shares of common stock (by category where available), and the closing share price of their company’s stock as of the “record date” for determining shareholders entitled to notice of, and to vote at, their company’s annual meeting, with footnotes where applicable.

    Unlike the first edition of this list last year (see “Top 20 Molecular Millionaires,” published in GEN October 2, 2012), all categories of shares of common stock were listed—not only the value of their shares of common stock as of the day they were tallied and recorded in filings, but shares of common stock which were exercisable or became so within a set period of time (typically 60 days) from the record date. The change reflects the fact numerous companies recorded the total number of shares of common stock for their largest shareholders—with explanations about multiple common stock categories in footnotes of the proxies or 20-F forms—in order to present a more complete picture of who owns what percentage of the companies’ stock. The change also explains why the top three on this list could better be described as molecular billionaires.

    The results showed the wealthiest molecular millionaires were officers, directors, former officers and directors, or investors of mature biotechs—typically those with products on the market, and the profits that follow. Several companies in that category could boast of having multiple executives, directors, or investors on this year’s list: Regeneron Pharmaceuticals led biotechs—and all companies, for that matter—with seven, followed by Vertex Pharmaceuticals (four), Bio-Rad Laboratories and Danaher (three each), and Bristol-Myers Squibb, Life Technologies, and Mettler Toledo (two each).

    The results reflect how good a year 2012 was for Regeneron and Vertex. In its proxy report, Regeneron noted the company overachieved its goals for last year, among them continued successful commercialization of Eylea (aflibercept) injection, including launch following FDA approval for a new macular edema indication; and FDA approval of Zaltrap (ziv-aflibercept) injection for IV infusion for use with Folfiri for metastatic colorectal cancer. Vertex launched Kalydeco for cystic fibrosis shortly after it gained FDA approval on August 31, 2012 and quickly racked up $171.6 million in sales, a figure expected to rise significantly this year.

    Big pharmas have only a small presence on this list, with only five executives and/or investors from four such companies appearing. Ranking highest among big pharmas, at No. 14, was not a current pharma exec but a retired chairman. The CEOs of two other pharma giants—Joseph Jimenez of Novartis, and Ian C. Read of Pfizer—narrowly missed the top 40.

  • #40. William P. Sullivan

    President and CEO, Agilent Technologies

    Total value of all shares: $41,064,949

    368,783 shares of common stock; 634,269 shares subject to options exercisable March 1, as of December 31, 20121

    Closing price on December 31, 2012: $40.94

  • #39. David F. Hoffmeister

    CFO, Life Technologies2

    Total value of all shares: $41,442,973

    691,177 shares of common stock as of March 63

    Closing price on March 6: $59.96

  • #38. Ian F. Smith

    EVP and CFO, Vertex Pharmaceuticals

    Total value of all shares: $41,800,057

    795,434 shares of common stock as of March 114

    Closing price on March 11: $52.55

  • #37. Charles A. Baker

    Director, Regeneron Pharmaceuticals

    Total value of all shares: $47,806,2035

    161,974 shares of common stock and 62,384 Class A shares as of April 176,7

    Closing price on April 17: $213.08

  • #36. Peter Mueller, Ph.D.

    EVP, Global Research and Development, and CSO, Vertex Pharmaceuticals

    Total value of all shares: $52,426,560

    997,651 shares of common stock as of April 178

    Closing price on April 17: $52.55

  • #35. George L. Sing

    Director, Regeneron Pharmaceuticals

    Total value of all shares: $53,434,498

    250,772 shares of common stock as of April 179

    Closing price on April 17: $213.08

  • #34. Marc N. Casper

    President and CEO, Thermo Fisher Scientific

    Total value of all shares: $56,122,022

    924,885 shares of common stock as of February 1110

    Closing price as of February 11: $60.68

  • #33. Robert J. Coury

    Executive Chairman of the Board, Mylan

    Total value of all shares: $57,074,91111

    1,087,411 shares of common stock; 879,333 shares with options exercisable and restricted shares vesting within 60 days as of March 26

    Closing price on March 26: $29.02

  • #32. Murray A. Goldberg

    SVP, Finance and Administration, CFO, and Secretary, Regeneron Pharmaceuticals

    Total value of all shares: $62,385,136

    292,778 shares of common stock as of April 1712

    Closing price on April 17: $213.08

  • #31. Robert F. Friel

    Chairman and CEO, PerkinElmer

    Total value of all shares: $63,378,82913

    516,849 shares of common stock; 1,340,134 shares acquirable within 60 days as of February 1514

    Closing price on February 15: $34.13

    Do you think giving large amounts of stock to key business officials is a fair method of compensating them?



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?